Ionis Pharmaceuticals (NASDAQ: IONS) keeps 2026 financial guidance unchanged

Rhea-AI Filing Summary

Ionis Pharmaceuticals, Inc. reaffirmed its previously announced financial guidance for the fiscal year ending December 31, 2026. The outlook remains unchanged from the financial guidance communicated on April 29, 2026 in its first quarter 2026 earnings release.

The company characterizes these expectations as forward-looking statements that involve risks and uncertainties related to discovering, developing and commercializing human therapeutics and building a business around them. It notes that actual results could differ materially if underlying assumptions do not materialize, and directs readers to its annual report for the year ended December 31, 2025 and its most recent quarterly report for a more detailed description of risks.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Terms

financial guidance, forward-looking statements, Section 18 of the Securities Exchange Act of 1934, Inline XBRL

4 terms

financial guidance financial

"reaffirming its previously announced financial guidance for the fiscal year ending December 31, 2026"

Financial guidance is the information that a company provides about its expected future financial performance, such as sales, profits, or expenses. It helps investors understand what the company aims to achieve and plan their decisions accordingly, much like a forecast or a roadmap that indicates the company's future direction. This guidance influences investor confidence and decision-making, as it offers insight into the company's outlook and growth expectations.

forward-looking statements regulatory

"This report contains forward-looking statements, including statements regarding the Company’s 2026 financial guidance"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Section 18 of the Securities Exchange Act of 1934 regulatory

"shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934"

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 07/10/2026 - 06:03 AM Accepted by SEC EDGAR 07/09/2026 - 09:03 PM Learn about SEC filing dates

FAQ

What did Ionis Pharmaceuticals (IONS) announce regarding its 2026 outlook?

Ionis Pharmaceuticals reaffirmed its financial guidance for the fiscal year ending December 31, 2026, stating that its outlook remains unchanged from guidance provided on April 29, 2026.

Is Ionis Pharmaceuticals (IONS) changing its previously issued 2026 financial guidance?

No. Ionis Pharmaceuticals stated that its 2026 financial guidance remains unchanged from the guidance it provided on April 29, 2026 in its first quarter 2026 earnings release.

How does Ionis Pharmaceuticals (IONS) describe the nature of its 2026 guidance?

Ionis describes its 2026 guidance as forward-looking statements involving risks and uncertainties related to drug discovery, development, commercialization and building a business around those medicines.

Where can investors find more risk information about Ionis Pharmaceuticals (IONS)?

Ionis points investors to its annual report on Form 10-K for the year ended December 31, 2025 and its most recent Form 10-Q, which provide additional risk details.

Does the Ionis Pharmaceuticals (IONS) reaffirmation filing affect liability under Section 18?

Ionis states that the information under this item shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to that section’s liabilities.

false0000874015NASDAQ00008740152026-07-092026-07-09

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

 PURSUANT TO SECTION 13 OR 15(d) OF THE

 SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  July 9, 2026

IONIS PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-19125		33-0336973
(Commission File No.)		(IRS Employer Identification No.)

2855 Gazelle Court

Carlsbad, CA 92010

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (760) 931-9200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock, $.001 Par Value		“IONS”		The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

  Emerging growth company                ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Ionis Pharmaceuticals, Inc. (the “Company”) is reaffirming its previously announced financial guidance for the fiscal year ending December 31, 2026, which remains unchanged from the financial guidance the Company provided on April 29, 2026 in its first quarter 2026 earnings release.

The information in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Forward-Looking Statements

This report contains forward-looking statements, including statements regarding the Company’s 2026 financial guidance and expected financial performance. Any statement describing the Company’s financial projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. The Company’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although the Company’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning the Company’s programs are described in additional detail in the Company’s annual report on Form 10-K for the year ended December 31, 2025, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Ionis Pharmaceuticals, Inc.
Dated:  July 9, 2026	By:	/s/ Patrick R. O’Neil
		Patrick R. O’Neil
		Executive Vice President, Chief Legal Officer and General Counsel

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 21.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 15.7 KB